From the RNAworld to the clinic

Science

Volumn 352, Issue 6292, 2016, Pages 1417-1420

  Sullenger, Bruce A ^a   Nair, Smita ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CODING RNA; MESSENGER RNA; RNA; RNA VACCINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; CANCER VACCINE; LONG UNTRANSLATED RNA; PROTEIN;

BIOMANIPULATION; CANCER; DISEASE INCIDENCE; DISEASE TREATMENT; DRUG DEVELOPMENT; GENETIC ANALYSIS; RNA;

ACTIVE IMMUNIZATION; CARDIOVASCULAR DISEASE; DENDRITIC CELL; EYE DISEASE; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; KIDNEY DISEASE; KIDNEY METASTASIS; LIVER DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL THERAPY; CELL REPROGRAMMING TECHNIQUE; GENETICS; PROCEDURES; PROTEIN SYNTHESIS;

ANIMALS; BIOLOGICAL THERAPY; CANCER VACCINES; CELLULAR REPROGRAMMING TECHNIQUES; HUMANS; IMMUNOTHERAPY; PROTEIN BIOSYNTHESIS; PROTEINS; RNA, LONG NONCODING; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84975045794     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aad8709     Document Type: Review

References (40)

1. J. C. Burnett, J. J. Rossi, Chem. Biol. 19, 60-71 (2012).
2. D. W. Drolet, L. S. Green, L. Gold, N. Janjic, Nucleic Acid Ther. 26, 127-146 (2016).
3. T. R. Cech, J. A. Steitz, Cell 157, 77-94 (2014).
4. D. Benteyn, C. Heirman, A. Bonehill, K. Thielemans, K. Breckpot, Expert Rev. Vaccines 14, 161-176 (2015).
5. S. Nair, D. Boczkowski, S. Pruitt, J. Urban, in Cancer Vaccines: From Research to Clinical Practice, A. Bot, M. Obrocea, F. M. Marincola, Eds. (CRC Press, ed. 1, 2011), pp. 217-231.
6. A. Bringmann, S. A. Held, A. Heine, P. Brossart, J. Biomed. Biotechnol. 2010, 623687 (2010).
7. S. Van Lint et al., Expert Rev. Vaccines 14, 235-251 (2015).
8. A. Amin et al., J. Immunother. Cancer 3, 14 (2015).
9. S. D. Allard et al., Clin. Immunol. 142, 252-268 (2012).
10. E. Van Gulck et al., AIDS 26, F1-F12 (2012).
11. V. F. Van Tendeloo et al., Blood 98, 49-56 (2001).
12. A. M. Van Nuffel et al., Cancer Immunol. Immunother. 61, 1033-1043 (2012).
13. D. A. Mitchell et al., Nature 519, 366-369 (2015).
14. I. Hoerr, R. Obst, H. G. Rammensee, G. Jung, Eur. J. Immunol. 30, 1-7 (2000).
15. R. D. Granstein, W. Ding, H. Ozawa, J. Invest. Dermatol. 114, 632-636 (2000).
16. U. Sahin, K. Karikó, Ö. Türeci, Nat. Rev. Drug Discov. 13, 759-780 (2014).
17. Y. Zhao et al., Cancer Res. 70, 9053-9061 (2010).
18. S. H. Yoon et al., Cancer Gene Ther. 16, 489-497 (2009).
19. G. L. Beatty et al., Cancer Immunol. Res. 2, 112-120 (2014).
20. J. Lee, C. M. Dollins, D. Boczkowski, B. A. Sullenger, S. Nair, Immunology 125, 229-240 (2008).
21. L. Warren et al., Cell Stem Cell 7, 618-630 (2010).
22. Y. Niu et al., Cell 156, 836-843 (2014).
23. G. McClorey, M. J. Wood, Curr. Opin. Pharmacol. 24, 52-58 (2015).
24. A. Fire et al., Nature 391, 806-811 (1998).
25. S. M. Elbashir et al., Nature 411, 494-498 (2001).
26. M. L. Bobbin, J. J. Rossi, Annu. Rev. Pharmacol. Toxicol. 56, 103-122 (2016).
27. J. Nemunaitis et al., Oncology 87, 21-29 (2014).
28. A. O. Garba, S. A. Mousa, Ophthalmol. Eye Dis. 2, 75-83 (2010).
29. V. Vigneswara et al., Brain 137, 1656-1675 (2014).
30. A. M. Ramos et al., Expert Opin. Drug Discov. 10, 541-556 (2015).
31. O. B. Suhr et al., Orphanet J. Rare Dis. 10, 109 (2015).
32. M. Hanna, Curr. Heart Fail. Rep. 11, 50-57 (2014).
33. B. A. Sullenger, H. F. Gallardo, G. E. Ungers, E. Gilboa, Cell 63, 601-608 (1990).
34. M. R. Mehan et al., Adv. Exp. Med. Biol. 735, 283-300 (2013).
35. C. P. Rusconi et al., Nature 419, 90-94 (2002).
36. A. M. Lincoff et al., Lancet 387, 349-356 (2016).
37. N. J. Ganson et al., J. Allergy Clin. Immunol. 137, 1610-1613 (2016).
38. N. Lan, R. P. Howrey, S. W. Lee, C. A. Smith, B. A. Sullenger, Science 280, 1593-1596 (1998).
39. J. A. Doudna, E. Charpentier, Science 346, 1258096 (2014).
40. Y. H. Kim et al., Theranostics 6, 357-368 (2016).